John Cuozzo of GSK to Present at GTCbio`s 3rd Assay Development and Screening Technologies Conference June 5-6
Released on: April 1, 2008, 2:19 pm
Press Release Author: GTCbio
Industry: Biotech
Press Release Summary: Dr. John W. Cuozzo, Director of ELT Lead Discovery at GlaxoSmithKline will present at GTCbio's 3rd Assay Development & Screening Technologies Conference on June 5-6, 2008 in San Francisco, CA. Dr. Cuozzo will speak on selecting hits from billions of compounds from encoded library technology.
Press Release Body: John Cuozzo, Director of ELT Lead Discovery at GlaxoSmithKline to Present at GTCbio's 3rd Assay Development & Screening Technologies Conference, June 5-6, 2008 in San Francisco, CA
MONROVIA, CA - Dr. John W. Cuozzo, Director of ELT Lead Discovery at GlaxoSmithKline will present at GTCbio's 3rd Assay Development & Screening Technologies Conference on June 5-6, 2008 in San Francisco, CA. Dr. Cuozzo will speak on selecting hits from billions of compounds from encoded library technology.
Recent technological advancements have improved the speed and reliability of high throughput screening but the total number of compounds that can be assayed using these methods has remained in the 10^6 range. Aptamer, phage, and antibody screening libraries have significantly greater diversity and can be rapidly queried for hits by selection. Encoded Library Technology (ELT) combines the power of affinity based enrichment with combinatorial chemistry to enable the rapid selection of hits from small molecule libraries containing up to several billion compounds. Each ELT library molecule carries a unique DNA tag which encodes the chemical composition of the small molecule. Libraries are \"selected\" against protein targets by affinity based methods. Enriched binders are isolated, sequenced, and translated back into their corresponding chemical structures. The hit compounds are then synthesized without the DNA tag and assayed for activity against the target. The presentation will describe how Dr. Cuozzo and his group have applied this technology to rapidly discover potent and selective hits against several different classes of drug target, and how they are continuing to refine their methods to improve success rate and focus selections on compounds with novel mechanisms of action.
GTCbio\'s 3rd Assay Development and Screening Technologies conference will provide attendees with critical information to utilize in the discovery and development of assays, while keeping them informed about the latest screening technologies for both high-throughput screening and high-content screening. Topics being covered include cell based assays, high throughput screening, high content screening, in vitro assays and screening, novel assay and screening technologies, and target validation. For more information visit www.gtcbio.com. ABOUT GTCbio GTCbio organizes conferences specifically for the biomedical and biopharmaceutical industries. Our goal is to facilitate the exchange of biopharmaceutical and biomedical intelligence between industry leaders, academic and government organizations, and the financial community. GTCbio is a subsidiary of Global Technology Community, LLC, a privately held company founded in 2002. Contact: GTCBIO (626) 256-6405, (626) 256-6460 fax, nina.tran@gtcbio.com
2022
